Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04248569
Recruitment Status : Recruiting
First Posted : January 30, 2020
Last Update Posted : August 12, 2021
Sponsor:
Collaborators:
Bristol-Myers Squibb
Fibrolamellar Cancer Foundation
Information provided by (Responsible Party):
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : March 2024
Estimated Study Completion Date : March 2024